vs
Side-by-side financial comparison of Envoy Medical, Inc. (COCH) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Sanara MedTech Inc. is the larger business by last-quarter revenue ($27.5M vs $75.0K, roughly 366.9× Envoy Medical, Inc.). Sanara MedTech Inc. runs the higher net margin — -5.9% vs -8781.3%, a 8775.5% gap on every dollar of revenue. On growth, Envoy Medical, Inc. posted the faster year-over-year revenue change (78.6% vs 4.6%). Sanara MedTech Inc. produced more free cash flow last quarter ($3.9M vs $-5.9M). Over the past eight quarters, Sanara MedTech Inc.'s revenue compounded faster (21.8% CAGR vs 12.7%).
Envoy Medical, Inc. is a medical technology firm specializing in developing and commercializing advanced implantable hearing solutions for sensorineural hearing loss patients. Its core products include fully implanted middle ear hearing devices, with primary markets across North America and Europe, serving users who gain limited benefit from conventional external hearing aids.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
COCH vs SMTI — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $75.0K | $27.5M |
| Net Profit | $-6.6M | $-1.6M |
| Gross Margin | -181.3% | 93.2% |
| Operating Margin | -8513.3% | 23.5% |
| Net Margin | -8781.3% | -5.9% |
| Revenue YoY | 78.6% | 4.6% |
| Net Profit YoY | -42.6% | 5.3% |
| EPS (diluted) | $-0.27 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $75.0K | $27.5M | ||
| Q3 25 | $42.0K | $26.3M | ||
| Q2 25 | $78.0K | $25.8M | ||
| Q1 25 | $46.0K | $23.4M | ||
| Q4 24 | $42.0K | $26.3M | ||
| Q3 24 | $56.0K | $21.7M | ||
| Q2 24 | $68.0K | $20.2M | ||
| Q1 24 | $59.0K | $18.5M |
| Q4 25 | $-6.6M | $-1.6M | ||
| Q3 25 | $-6.5M | $-30.4M | ||
| Q2 25 | $-5.7M | $-2.0M | ||
| Q1 25 | $-5.0M | $-3.5M | ||
| Q4 24 | $-4.6M | $-1.7M | ||
| Q3 24 | $-6.0M | $-2.9M | ||
| Q2 24 | $-3.9M | $-3.5M | ||
| Q1 24 | $-6.3M | $-1.8M |
| Q4 25 | -181.3% | 93.2% | ||
| Q3 25 | -383.3% | 92.9% | ||
| Q2 25 | -200.0% | 92.5% | ||
| Q1 25 | -391.3% | 92.2% | ||
| Q4 24 | -273.8% | 91.4% | ||
| Q3 24 | -233.9% | 90.8% | ||
| Q2 24 | -260.3% | 90.0% | ||
| Q1 24 | -159.3% | 89.8% |
| Q4 25 | -8513.3% | 23.5% | ||
| Q3 25 | -13590.5% | 11.2% | ||
| Q2 25 | -6500.0% | -0.1% | ||
| Q1 25 | -11102.2% | -8.9% | ||
| Q4 24 | -10828.6% | 18.6% | ||
| Q3 24 | -8878.6% | 3.6% | ||
| Q2 24 | -7135.3% | -14.3% | ||
| Q1 24 | -8278.0% | -8.3% |
| Q4 25 | -8781.3% | -5.9% | ||
| Q3 25 | -15433.3% | -115.5% | ||
| Q2 25 | -7294.9% | -7.8% | ||
| Q1 25 | -10865.2% | -15.1% | ||
| Q4 24 | -10995.2% | -6.5% | ||
| Q3 24 | -10642.9% | -13.2% | ||
| Q2 24 | -5804.4% | -17.4% | ||
| Q1 24 | -10627.1% | -9.5% |
| Q4 25 | $-0.27 | $-0.32 | ||
| Q3 25 | $-0.35 | $-3.40 | ||
| Q2 25 | $-0.32 | $-0.23 | ||
| Q1 25 | $-0.29 | $-0.41 | ||
| Q4 24 | $-0.40 | $-0.18 | ||
| Q3 24 | $-0.39 | $-0.34 | ||
| Q2 24 | $-0.29 | $-0.41 | ||
| Q1 24 | $-0.41 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $16.6M |
| Total DebtLower is stronger | — | $46.0M |
| Stockholders' EquityBook value | $-12.2M | $5.9M |
| Total Assets | $8.6M | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $16.6M | ||
| Q3 25 | — | $14.9M | ||
| Q2 25 | — | $17.0M | ||
| Q1 25 | — | $20.7M | ||
| Q4 24 | — | $15.9M | ||
| Q3 24 | — | $16.3M | ||
| Q2 24 | — | $6.2M | ||
| Q1 24 | — | $2.8M |
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $-12.2M | $5.9M | ||
| Q3 25 | $-7.7M | $6.1M | ||
| Q2 25 | $-29.9M | $35.4M | ||
| Q1 25 | $-24.2M | $36.7M | ||
| Q4 24 | $-18.8M | $39.4M | ||
| Q3 24 | $-18.5M | $39.8M | ||
| Q2 24 | $-12.4M | $41.7M | ||
| Q1 24 | $-7.4M | $43.3M |
| Q4 25 | $8.6M | $72.9M | ||
| Q3 25 | $8.2M | $71.1M | ||
| Q2 25 | $9.9M | $98.8M | ||
| Q1 25 | $10.4M | $96.4M | ||
| Q4 24 | $11.5M | $88.1M | ||
| Q3 24 | $9.4M | $88.5M | ||
| Q2 24 | $6.7M | $73.4M | ||
| Q1 24 | $8.5M | $70.9M |
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.7M | $3.9M |
| Free Cash FlowOCF − Capex | $-5.9M | $3.9M |
| FCF MarginFCF / Revenue | -7809.3% | 14.0% |
| Capex IntensityCapex / Revenue | 229.3% | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.7M | $3.9M | ||
| Q3 25 | $-4.3M | $2.2M | ||
| Q2 25 | $-4.5M | $2.7M | ||
| Q1 25 | $-3.7M | $-2.0M | ||
| Q4 24 | $-5.1M | $932.0K | ||
| Q3 24 | $-2.6M | $2.1M | ||
| Q2 24 | $-4.6M | $-1.4M | ||
| Q1 24 | $-5.6M | $-1.6M |
| Q4 25 | $-5.9M | $3.9M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $-4.5M | $902.7K | ||
| Q1 25 | $-3.7M | $-3.7M | ||
| Q4 24 | — | $859.9K | ||
| Q3 24 | $-3.8M | $2.0M | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | $-5.7M | $-1.7M |
| Q4 25 | -7809.3% | 14.0% | ||
| Q3 25 | — | 4.2% | ||
| Q2 25 | -5719.2% | 3.5% | ||
| Q1 25 | -8110.9% | -15.9% | ||
| Q4 24 | — | 3.3% | ||
| Q3 24 | -6750.0% | 9.4% | ||
| Q2 24 | — | -7.3% | ||
| Q1 24 | -9657.6% | -9.0% |
| Q4 25 | 229.3% | 0.3% | ||
| Q3 25 | 0.0% | 4.0% | ||
| Q2 25 | 1.3% | 6.8% | ||
| Q1 25 | 13.0% | 7.4% | ||
| Q4 24 | — | 0.3% | ||
| Q3 24 | 2066.1% | 0.0% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | 184.7% | 0.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COCH
Segment breakdown not available.
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
